Immorna
PrivateLast Round
Grant
Aug 26, 2024
Total Funding Raised
$118.8M
Company Overview
Immorna is a biotechnology company that develops mRNA-based therapeutics and vaccines for cancer immunotherapy, infectious diseases, and rare genetic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immorna Comparables
Compare Immorna with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Innorna | 87% | |
| Bristol Myers Squibb | 83% | |
| Abogen Biosciences | 83% | |
Immorna Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Aug 26, 2024 | ||||
| Series A Extension | Feb 27, 2023 | ||||
| Series A | Jan 18, 2021 | ||||
| Seed | Dec 13, 2019 |
Immorna Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Alwin Capital | Seed |
| China Chengtong Fund Management Co., Ltd. | Series A Extension |
| Zheshang Venture Capital | Series A Extension, Series A |
| Hillhouse Investment | Series A Extension |
| Co-Win Ventures | Series A Extension, Seed, Series A |
| Tigeryeah Capital | Series A Extension |
| Gates Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 26, 2024
Received $4M from the Bill & Melinda Gates Foundation.
- Feb 27, 2023
$100M round with participation from Xiamen C&D, Co-Win Ventures, and others.
Immorna Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Immorna's valuation, stock price, and market status.